The role of virgin olive oil components in the modulation of endothelial function by Perona, Javier S. et al.
 1 
 
 
 
 
 
The Role of Virgin Olive Oil Components on the 
Modulation of Endothelial Function 
  
Javier S. Perona, Rosana Cabello-Moruno, Valentina Ruiz-Gutierrez* 
 
Instituto de la Grasa (CSIC). Av. Padre García Tejero, 4. 41012. Seville. Spain. 
 
 
 
 
 
 
 
*Corresponding author. 
Running title: Olive oil and endothelial function. 
Key-words: virgin olive oil, endothelium, nitric oxide, reactive oxygen species, adhesion 
molecules. 
 
 
 
 
 
 
* Manuscript
 2 
Abstract 
 
The endothelium is involved in many of the processes related to the development of 
atherosclerosis, which is considered an inflammatory disease. Actually, traditional risk factors 
for atherosclerosis predispose to endothelial dysfunction, which is manifested as increase in 
the expression of specific cytokines and adhesion molecules. There is firm evidence 
supporting the beneficial effects of olive oil, as the most genuine component of the 
Mediterranean diet. Although the effects of olive oil and other oleic acid-rich dietary oils on 
atherosclerosis and plasma lipids are well-known, the roles of minor components have been 
less investigated. Minor components constitute only 1-2% of virgin olive oil and are 
comprised of hydrocarbons, polypohenols, tocopherols, sterols, triterpenoids, as well as other 
components usually found in traces. Despite their low concentration, non-fatty acid 
constituents may be of importance, since studies comparing monounsaturated dietary oils 
have reported different effects on cardiovascular disease. Most of these compounds have 
demonstrated antioxidant, anti-inflammatory and hypolipidemic properties. In the present 
review we summarize the current knowledge on the effects of these compounds contained in 
virgin olive oil on vascular dysfunction and the mechanisms by which they modulate 
endothelial activity. Such mechanisms involve the release of nitric oxide (NO), eicosanoids 
(protaglandins and leukotrienes) and adhesion molecules, in most cases by activation of 
nuclear factor κB (NFκB) by reactive oxygen species (ROS). 
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1. Endothelial dysfunction in cardiovascular disease 
 
1.1. Nature of the atherosclerotic process 
 
Atherosclerosis remains as the leading cause of death in the developed countries and is on 
track to become the most common cause of disease-related disability and death by the year 
2020 [1,2]. Although several theories have been proposed for the pathogenesis of 
atherosclerosis, the current trend is to consider it as a response of the vascular wall to a 
variety of agents and mechanisms, which contribute to the development of the atheromatous 
plaque [3]. The vascular endothelium is an active and dynamic monolayer of cells, which 
serves as a semipermeable barrier between blood an tissue [4]. Due to this strategic location it 
is involved in maintaining homeostasis, by sensing changes in hemodynamic forces and 
signals and responding to them by releasing bioactive substances [5,6].  
 
 Traditional risk factors for atherosclerosis, which is considered an inflammatory disease, 
predispose to endothelial dysfunction and activation of the endothelium [7]. This activation is 
manifested as an increase in the expression of specific cytokines and adhesion molecules, 
such as intracellular adhesion molecule (ICAM-1), vascular cell adhesion molecule (VCAM-
1) and E-selectin [8,9]. Circulating monocytes are attracted by these molecules and adhered to 
the endothelium, from which they transmigrate to the subendothelial space. Once within the 
endothelium, monocytes differentiate into macrophages, which scavenge oxidized LDL and 
triglyceride-rich lipoproteins (TRL), becoming foam cells and contributing to the formation of 
the atheroma in the early stages of the atherosclerotic process [7]. 
 
1.2. Function of endothelial cells. 
 
The endothelium has a major function in thrombotic and coagulant activities, synthesizing 
several molecules that are released in response to different stimuli [10]. Heparan sulfate, nitric 
oxide [NO] and prostacyclin are vasodilators, whereas thromboxane A2, prostaglandin H2 and 
endothelin 1 are vasoconstrictors [11, 12]. NO is the primary endothelial-derived relaxing 
factor playing a pivotal role in vascular reactivity [13]. It inhibits platelet aggregation [13], 
alters cell adhesion molecule expression and inhibits proliferation of smooth muscle cells [14]. 
NO is generated in the endothelial cell by NO synthase (eNOS), which converts the 
aminoacid L-arginine to NO and L-citrulline. NO diffuses from the endothelial cell to the 
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vascular smooth muscle and increases cyclic guanosine monophosphate, thereby causing 
relaxation of smooth muscle and dilation of the artery.  
 
Endothelial dysfunction occurs early in the development of atherosclerosis, even before the 
formation of the plaque [15]. Clinical studies have revealed that risk factors for 
atherosclerosis, such as smoking, hypercholesterolemia, hypertension, diabetes and 
hyperhomocysteinemia, predispose to endothelial dysfunction [7]. When dysfunctional, the 
endothelium increases flow disturbances due to improper vasoreactivity. Most importantly, it 
initiates inflammatory responses by releasing proinflammatory cytokines and chemokines. 
Thus, it increases leukocyte activation, promotes monocyte adhesion molecule expression and 
facilitates entry of monocytes and lipoproteins into the subendothelial space [16]. 
 
1.3. Measurement of endothelial function. 
 
Reliable assessment of endothelial function in humans seems to be of major importance 
and can be achieved by different approaches. The determination of soluble endothelial 
markers in blood is the most common and will be discussed later in this review. However, 
direct measurement of endothelial function would be desirable. Vasodilation can be 
measured after intra-arterial pharmacologic stimulation with substances that enhance NO 
release but this method is highly invasive. The most promising non-invasive method is the 
measurement of the flow-mediated dilation (FMD) in the brachial artery by Doppler 
ultrasonography. This technique is based on the endothelium sensitivity to shear stress, 
which elicits NO release and dilation of underlying smooth muscle [17]. Shear stress is 
caused by hyperemia (induced by cuff inflation and then deflation) and, in these conditions, 
FMD appears to be mediated mostly by NO (70%) and prostacyclin (30%) [17,18]. Thus, 
FMD may also serve as an index of NO bioavailability [19]. The endothelial signaling 
cascade responsible to concert mechanic stimuli into the release of vasodilatory molecules is 
nor fully known. Although some mechanisms have been suggested, it is probable that it 
involves phosphorylation of a serine residue of eNOS by shear stress, altering its sensitivity 
to intracellular calcium levels and hence increasing NO formation [20]. 
 
There is ample evidence that FMD is diminished in patients with atherosclerosis and 
coronary risk factors and that it can detect endothelial dysfunction in hyperlipidemia, 
hypertension and diabetes [21-23]. FMD has been shown to be decreased after a single high-
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fat meal and postprandial lipemia [24], however there are very scarce data on the effect of 
olive oil. Vogel et al. [25] found a decrease in FMD after olive oil-rich meals compared with 
canola oil and salmon, which was attributed to oxidative stress because the decrease in FMD 
was reduced by the concomitant administration of vitamins C and E.  However, these results 
should be confirmed with further investigations. 
 
2. Factors that influence endothelial function 
 
2.1. Reactive oxygen species impair the activity of nitric oxide 
 
There is ample evidence indicating that increased vascular free oxygen levels are the prime 
mechanism for endothelial dysfunction [6]. ROS may be produced during normal metabolism 
or after oxidative processes and include superoxide anion (O2-) and hydrogen peroxide (H2O2) 
[26]. The contribution of NO and ROS to the vascular tone is inversely proportional to each 
other and the appearance of one could likely compensate for the absence of the other [27]. 
The formation of ROS is balanced by a range of antioxidant defenses, but the excess, as in 
several cardiovascular risk factors like hypercholesterolemia, hypertriglyceridemia or high 
postprandial triglyceridemia, can overwhelm these systems, leading to oxidative stress.  
 
2.1.1. Effect of hypercholesterolemia on endothelial dysfunction 
 
Hypercholesterolemia [28,29], diabetes mellitus [30] and hypertension [31,32] are related 
to increased production of superoxide anion. This anion reacts rapidly with NO to form 
peroxynitrite (OONO-) thus inactivating NO and leading to endothelial dysfunction. ROS can 
also react with polyunsaturated fatty acids (PUFA) contained in lipoproteins in the vessel wall 
initiating lipid peroxidation. The hydroperoxides formed in this process can in turn react with 
NO to form peroxynitrites, inactivating NO and can directly decrease the endothelial 
synthesis of NO [33]. In addition, altered LDL are not recognized by LDL receptors, which 
are saturable, and instead are taken up by macrophages through scavenger receptors, not 
saturable, eventually becoming foam cells. Antioxidants constitute a diverse group of 
compounds among whose effects includes inhibition of LDL oxidation by both reductions in 
the concentration and reactivity of oxidants and improved resistance of the particle to them 
[34]. The antioxidants that have received the most attention are vitamin C (ascorbic acid), 
vitamin E (α-tocopherol) and phenolic compounds. In contrast to LDL, HDL provides an 
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atheroprotective effect by inhibiting cytokine-induced endothelial cell adhesion molecule 
expression [35] and by enhancing agonist-induced vasodilation in coronary arteries [36]. 
 
2.1.2. Effect of hypertriglyceridemia on endothelial dysfunction 
 
There is evidence that hypertriglcyeridemia-induced endothelial dysfunction plays a 
critical role in this pathology. Traditionally, fasting triglyceride (TG) concentrations have not 
been considered as an indicator of coronary artery disease (CAD). The metabolic relation 
between TRL and HDL, the heterogeneity of TRL and the imprecision by which serum TG 
are determined contribute to the erosion of the relationship between TG and CAD [37,38]. 
However, the serum TG concentration is often more strongly correlated with future CAD 
incidence in multivariate analysis than is serum cholesterol [39]. Considering this evidence 
and that the TG metabolism also determines the fate of some other lipoproteins, such as LDL 
or HDL [40], TG seem to have a central role in the pathogenesis of atherosclerosis. 
 
Disorders in TG metabolism may promote atherogenesis by increasing expression of 
vascular cell adhesion molecules. The concentrations of E-selectine, ICAM-1 and VCAM-1 
are increased in the serum of patients with hypertriglyceridemia, independently of other risk 
factors [41].  
 
2.1.3. Effect of postprandial triglcyeridemia on endothelial dysfunction 
 
Postprandial triglyceridemia is also a good predictor of the presence and progression of 
atherosclerosis [42]. TRL, comprising TG contained in chylomicrons (CM) and VLDL, as 
well as their remnants, can cross the endothelial barrier and enter the arterial wall [43] and can 
be taken up by macrophages without need of further oxidation of the particles [44]. It has 
been suggested that the entry of lipoproteins into the arterial wall is inversely related to the 
size of the particles, and for that reason, it was thought for many years that TRL were not 
atherogenic, since they are too large to penetrate the tissue [45,46]. However, the TRL 
remnants formed after the hydrolytic activity of lipoprotein lipase (LPL) and endothelial 
lipase (EL) can enter the arterial intima and thus, be more atherogenic than their nascent 
precursors [47].  
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In vitro studies of endothelial cells reported that LPL-derived TRL remnants isolated from 
hypretriglyceridemic subjects have the ability of disrupt endothelial integrity [48,49]. It has 
been shown that remnant-like lipoprotein particles (RLPs) have a causative role in endothelial 
vasomotor dysfunction in human coronary arteries and that RLPs directly induced endothelial 
dysfunction in the isolated rabbit aorta [50,51]. In fact, TRL and their remnants stimulate 
endothelial cell plasminogen activator inhibitor-1 [PAI-1] production [52], which is a marker 
of endothelial dysfunction, and cause a profound depression of fibrinolytic activity [53]. TRL 
remnants also promote an enhanced thrombogenic tendency by increasing circulating factor 
VII levels [54].  
 
In addition, it has been reported that monocyte adhesion to endothelial surface is enhanced 
by TRL [55,56]. CM preparations obtained from human plasma 4h after a standard fat-
containing meal, were shown to up-regulate the expression of E-selectin and VCAM-1. 
Interestingly, TRL did not require LPL to promote the expression of adhesion molecules, 
suggesting that these particles may be pro-inflammatory themselves independently of their 
ability to release fatty acids [57]. Doi et al. [56] confirmed the up-regulation of protein and 
mRNA expression of these adhesion molecules when endothelial cells were incubated with 
TRL obtained from hypertriglyceridemic patients and they extended it to ICAM-1 and tissue 
factor (TF). 
 
The oxidative mechanism can at least partially explain the adverse effects of TRL on 
endothelial cell function. TRL accumulation in plasma leads to increased oxidative stress and 
decreased NO availability as it is associated with increase of vascular superoxide anion 
production [58]. In their study, Doi et al. [56] observed increased cellular oxidant levels in the 
endothelial cell incubation medium containing TRL and that co-incubation with α-tocopherol 
decreased the concentrations of ICAM-1 and VCAM-1.  
 
Hydrolytic enzymes, such as LPL and EL may be directly implicated in endothelial 
dysfunction, as their synthesis is up-regulated in early atherosclerosis [59]. Apart from 
smooth muscle cells, LPL is produced by monocytes and macrophages [60-63 ]. There is 
evidence that LPL activity can enhance the retention of LDL and VLDL to the arterial wall 
[64,65], but also it facilitates proteoglycan-mediated monocyte adhesion to the endothelium 
[66]. Actually, inflammatory cytokines, such as TNF-α and IL-1β can up-regulate endothelial 
derived LPL mRNA [67]. In contrast to LPL, EL is synthesized in the endothelium and has a 
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primary phospholipase activity [68]. However, its mRNA expression is also increased in 
endothelial cells by TNF-α and IL-1β [67]. The upregulation of these enzymes is thought to 
be mediated via the nuclear factor κB (NF κB) pathway [69]. NFκB can be activated by a 
number of stimuli, including lipids and ROS. These stimuli cause the phosphorilation of IκB 
and subsequent proteolytic degradation of this inhibitor subunit, allowing NFκB to translocate 
into de nucleus, where it binds to recognition sequences in DNA in order to induce gene 
expression [70].  
 
2.2. Beneficial and adverse effects of dietary fatty acids. 
 
It has been postulated that as energy needs are increased during acute inflammation, 
lipolytic enzymes are up-regulated as a way of generating free fatty acids from circulating 
lipoproteins to be used by the tissues, including the endothelium. The increase in free fatty 
acid concentrations in the endothelium has been shown to decrease endothelial NO bioactivity, 
due to both superoxide generation and reduction in eNOS activity [71,72]. In vitro studies 
suggest that PUFA are more pro-inflammatory than monounsaturated (MUFA) and saturated 
(SFA) fatty acids [73]. In fact, linoleic acid (18:2, n-6) has greater capacity to induce 
oxidative and inflammatory stress than other fatty acids. Incubation of this fatty acid with 
endothelial cells promotes NFκB activation and transcriptional activity, being this effect is 
attenuated by vitamin E [74]. Additionally, exposure of endothelial cells to linoleic acid can 
lead to production of cytokines, such as IL-6 and IL-8 [75], which are involved in the 
initiation and progression of atherosclerosis [76,77].  
 
Conversely, n-3 PUFA are believed to exert an endothelial protective effect. Particularly, 
docosahexaenoic acid (22:6, n-3; DHA) decreases expression of VCAM-1 on the vascular 
endothelium and monocyte adhesion [78-80] and eicosapentaenoic acid (20:4, n-3; EPA) 
increases NO production. Although these results from in vitro studies are promising, in vivo 
studies were more controversial. Abe et al. [41] found no reduction in soluble adhesion 
molecules after 6 weeks in patients receiving n-3 fatty acids but did find reductions in ICAM-
1 and E-selectin after 7 months. Seljeflot et al. [81] supplemented male smokers with n-3 fatty 
acids for 6 weeks finding reductions in pro-thrombogenic von Wilebrand factor but increase 
in VCAM-1 and E-selectin. Their results were corroborated by Johansen et al. [82].  
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Among the key inflammatory mediators released by the endothelium are the eicosanoids 
derived from the n-6 PUFA arachidonic acid (20:4, n-6; AA). Prostaglandin E2 (PGE2) can 
cause pain and vasodilation and leukotriene B4 (LTB4) is a chemoatractant and activator of 
neutrophils. They are formed from AA via the cyclooxygenase (COX) and 5-lipooxygenase 
(LOX) pathways, respectively. However, EPA is also a potential COX substrate and can 
compete with AA for this enzyme leading to formation of PGE3, which is synthesized with 
very low efficiency [83]. EPA is also substrate for LOX forming LTB 5, with less 
inflammatory activity compared to LTB4 [84,85]. Thus, increasing the n-3 content in the diet, 
the balance of the eicosanoids produced can be shifted to a less inflammatory mixture.  
 
3. Evidences of the benefits of olive oil on cardiovascular disease 
 
A number of epidemiological studies developed in different countries constitute a firm and 
reliable experimental base supporting the beneficial effects of the Mediterranean diet, rich in 
olive oil, in regard to the reduction of CAD [86].  
 
The Seven Countries Study, initiated by Ancel Keys in 1970 [87], was designed to investigate 
relationships between diet and CAD comparing different populations. The results of this study 
showed that the population of the Mediterranean island of Crete had the lowest rates of CAD 
and cancer, concluding that the cause might be the low saturated fat and high oleic acid 
intake, in terms of olive oil, of the Mediterranean diet. Subsequently, the Lyon Diet Heart 
Study [88] developed on patients recovering from a myocardial infarction, was the first 
clinical evidence in support of the health benefits of a Mediterranean-style diet, similar to that 
of Crete. The protective effects were ascribed to higher intakes of oleic acid and α-linolenic 
acid (18:3, n-3) and lower intakes of saturated fatty acids and linoleic acid (18:2, n-6). 
Trichopoulou et al. [89], demonstrated that the adherence to a Mediterranean diet reduced 
mortality from cancer and coronary heart disease in a Greek population of more than 22,000 
individuals. These results were more recently confirmed in subjects diagnosed of CHD [90].  
 
Cumulative evidence suggests that MUFA may be key components in the protective role of 
the Mediterranean Diet [91]. In fact, MUFA are believed to be as effective as n-6 PUFA at 
lowering total and LDL-cholesterol when replacing saturated fatty acids, as supported by two 
meta-analyses [92,93]. In addition, it has been reported that a controlled olive oil-based diet 
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can even lower plasma triacylglycerol levels [94], although there is some controversy in this 
regard [95,98].  
 
It is probable that arterial hypertension resulted to be “quantitatively” the most important risk 
factor for CHD, due to its repercussion on cardiovascular mortality [99]. Diets enriched in n-3 
PUFA are known to reduce blood pressure in humans [100,101] and in Spontaneously 
Hypertensive Rats (SHR) [102], which has been related to increased synthesis of series n-3 
eicosanoids, with a stronger vasodilator effect than their series n-6 homologous [103]. 
However, there is increasing evidence showing that olive oil reduces systolic and diastolic 
blood pressure in normotensive [14,105] and hypertensive individuals [106]. Recently, 
another study including participants that had never received a diagnosis of hypertension 
confirmed these results. It concluded that the Mediterranean diet is inversely associated with 
arterial blood pressure and that olive oil intake, per se, is inversely associated with both 
systolic and diastolic blood pressure [107]. The modification in blood pressure by dietary 
olive oil has been related to changes in the fatty acid composition of cell membrane, which 
affects its functionality [106,108].  
 
Oxidative modification of LDL is an important determinant in the development of 
atherosclerosis, as it accelerates the uptake of LDL by macrophages, which is the beginning 
of formation of a fatty streak. LDL may be protected against attacks of free radicals by 
antioxidants in plasma and in the particle itself. Lipoproteins rich in MUFA after long-term 
consumption of olive oil have been shown to be less susceptible to oxidation compared to 
particles enriched in PUFA [109-113].  
  
An increasing number of studies point out that the content of oleic acid alone can not fully 
explain the impact on health of olive oil. This conclusion has been drawn from studies 
comparing the effects of diets enriched in different monounsaturated oils [114], among which 
VOO and high oleic sunflower oil (HOSO) have been most widely used.  
 
Unlike VOO, HOSO was not able to reduce the blood pressure, in hypertensive patients 
[106]. Further studies in humans revealed that this differential effect was related to the 
composition and functionality of the cell membrane of hypertensive patients [106,115]. In 
SHR, VOO and HOSO yield to different liver, adipose tissue and myocardium lipid 
composition [116-118] and vascular reactivity [119]. These differences may be consequence 
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of a differential incorporation of the components of VOO and HOSO into TRL [120-122]. 
Actually, postprandial lipoproteins obtained after ingestion of VOO or HOSO are 
differentially incorporated into vascular cells [123], from which release of eicosanoid 
substances is also affected [124]. Furthermore, it has been reported that LDL from olive oil-
fed rats were more resistant to oxidation in vitro than those isolated from plasma of triolein-
fed rats [125]. The differential effects of different oleic acid-rich oils on LDL oxidation were 
confirmed in ten normolipidemic subjects by Nicolaiew et al., [126] after administration of 
VOO or HOSO. These data support the idea that the protective effects of olive oil against 
CAD must not be attributed exclusively to oleic acid, but to some other components of the oil. 
 
Among the differential characteristics of VOO, the quantitatively most important is the TG 
molecular species composition. Compared to HOSO, which contains mainly triolein, VOO 
contains also important amounts of dioleoy-palmitoyl-glycerol. In much lower concentrations, 
but with growing evidence of important biological effects, minor components of olive oil can 
be also used to differentiate this oil from others.  
 
4. Chemical composition of olive oil 
 
In contrast to most dietary oils, which are obtained from the seeds of the plants by means of 
solvent extraction, and refined before being edible, olive oil is obtained from the whole fruit 
of Olea Europaea L, only by physical pressure. This procedure makes olive oil unique, since 
some compounds that cannot be found in other dietary oils are transferred from the leaves and 
skin of the fruit to the oil.  
Olive oil can be classified into two fractions from a quantitative point of view. The major 
fraction constitutes 98-99% of the oil and it is mainly composed of saponifiable glyceridic 
compounds as triacylglycerols (TG). The abundance of oleic acid is peculiar to olive oil and 
ranges from 60-84% of total fatty acids in TG, while linoleic acid, the major essential fatty 
acid and the most abundant polyunsaturated acid in our diet, is present in concentrations 
between 3-21%.  
 
Minor compounds account for the rest 1-2%, comprising unsaponifiable compounds, 
phenolics and waxes, and despite of being a little proportion, they confer important biologic 
activities. The minor compounds of VOO, classified in growing order of polarity after 
developed by thin-layer chromatography are: hydrocarbons, tocopherols, fatty alcohols, 4-
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methylesterols, sterols, triterpenic dialcohols, polar-coloured pigments and phenolic 
compounds [127].   
 
One of the greatest differences between VOO and the rest of edible oils is the composition in 
hydrocarbons [128]. Among them, the most important is squalene [129], a polyunsaturated 
triterpene that appears at high concentration and makes up 60-75% of the unsaponifiable 
fraction of the olive oil [130], and it is a precursor in the biosynthesis of cholesterol and 
steroid hormones. β-carotene is also found within this group, a triterpenic polyunsaturated 
hydrocarbon which plays an important role as precursor of vitamin A and, along with 
lycopene, conferring the yellowish colour to the oil. The analysis of the sterol fraction is of 
importance because it helps to the characterisation of the species from which the oil has been 
extracted [131]. The main sterol found in virgin olive oil is β-sitosterol [95%] but 
campesterol, ∆-7 stigmastenol, stigmasterol, spinasterol and avenasterol are also present. 
VOO contains α, β, γ and ∆-tocopherols, but α-tocopherol typically accounts for more than 
85% of total tocopherols. Triterpenic dialcohols and acids, from the skin of the fruit and from 
the leaves are incorporated in second pressing oil and the final concentration is higher than in 
VOO. The main dialcohol is known as erythrodiol, which in some cases, is accompanied by 
another triterpenic-tetracyclic diol identified as uvaol. Among acids, oleanolic and maslinic 
have recently revealed some pharmacological properties, which will be discussed below. 
 
Phenolic compounds are rarely determined in routine analysis because of their solubility in 
water and diluted bleach, what explains their absence from both unsaponifiable and glyceridic 
fractions. These substances constitute the ‘polar fraction’ in VOO and underlay its 
exceptional thermal stability [132-134], contribute to its characteristic flavour and taste, and 
prevent its autooxidation, contributing to the resistance of VOO to oxidative rancidity [135]. 
Phenolic compounds have emerged as potent antioxidants present in VOO. Among these 
compounds, oleuropein itself and its derivatives, tyrosol and hydroxytyrosol, have been 
reported to have a protective role against LDL oxidation in vitro, equivalent to vitamin E 
[136]. Although it has been demonstrated that VOO phenolics are dose-dependently absorbed 
in humans [137], in plasma they are mostly present as conjugates of glucuronic acid. The in 
vivo antioxidant effect of VOO phenolics and the antioxidant capacity of the glucuronidates 
are scarce and controversial. However, interventional studies administrating increasing doses 
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of phenolic compounds in VOO have reported reduced oxidative status in healthy [138,139] 
and dyslipemic subjects [140].  
 
 
5. Effects of the components of olive oil on the endothelial function 
 
Very few studies have addressed the effects of long-term olive oil consumption on the 
endothelial function. Mediterranean diet, rich in olive oil, has been shown to improve 
endothelial function in diabetic [141] and hypercholesterolemic patients [142], as assessed by 
measuring endothelium-dependent vasoreactivity. Fuentes et al., [142] also observed a 
reduction in the plasma levels of P-selectin. In a randomized crossover trial, Ros et al. [143] 
confirmed the improvement on endothelial function in 22 hypercholesterolemic subjects 
receiving a Mediterranean diet. However, the results were more evident when part of the 
dietary olive oil was replaced with walnuts. Sondergaard et al., [144] observed a greater 
improvement in flow-mediated vasodilation (FMD) in patients receiving fluvastatin when 
they were advised of following a Mediterranean diet. Esposito et al. [145] carried out a 
randomized trial among 180 subjects with metabolic syndrome, who were instructed to follow 
a Mediterranean-style diet, including olive oil. After two year follow-up, they observed 
improved endothelial function as a measure of blood pressure and platelet aggregation 
response to L-arginine, the natural precursor of nitric oxide. They also reported a significant 
reduction of markers of systemic vascular inflammation, such as C-reactive protein and 
interleukins 6 (IL-6), 7 (IL-7) and 18 (IL-18), apart from total and LDL-cholesterol. However, 
the mechanisms by which dietary olive oil elicits these effects and which are the actual 
components of the oil responsible for the effects are poorly elucidated. Below, we show the 
current knowledge on the effects of the components of olive oil on endothelial activation. A 
graphic summary of the mechanisms is depicted on Figure 1. 
 
 
5.1. Effects of major components of olive oil on endothelial function 
 
5.1.1. Effects of oleic acid 
 
Oleic acid, the main fatty acid contained in olive oil, accounts for about 29% of the daily 
caloric intake in some Mediterranean countries. Recent studies testing the role of different 
unsaturated fatty acids in endothelial cell activation and injury, suggest that oleic acid does 
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not activate endothelial cells confirming its benefits on early events in atherosclerosis 
compared with other unsaturated fatty acids [146]. Carluccio et al. [147] reported that plasma 
concentration of oleate under conditions of high olive oil consumption are likely to be fully in 
the range of concentrations exerting biological effects in our system, likely between 10 and 
100 µmol/L. 
 
Tsimikas et al. [148] assessed the proinflammatory potential of LDL isolated from Greek 
subjects consuming a diet naturally rich in olive oil. Oleic acid content in LDL was 
significantly higher in the Greek compared Americans and was inversely correlated with the 
extent of in vitro LDL oxidation and the induction of monocyte adhesion by mildly oxidized 
LDL. To confirm that dietary fatty acids influence the proinflammatory properties of mildly 
oxidized LDL, native LDL were also isolated from American subjects after consumption of a 
liquid diet supplemented with either oleic or linoleic acid. The oleic acid-supplemented group 
had higher oleic and lower linoleic acid content in LDL than the linoleate-supplemented 
group. When exposed to oxidative stress, the LDL enriched in oleic acid promoted less 
monocyte chemotaxis and reduced monocyte adhesion, showing a strong negative correlation 
between oleic acid LDL content and monocyte adhesion. This study demonstrated that the 
level of dietary enrichment with oleic acid necessary to obtain these benefits is realistic and 
readily achieved by using diets currently in use in Mediterranean countries. Also, this study 
suggested that LDL enriched with oleic acid and reduced in PUFA may be less easily 
converted to a proinflammatory, minimally modified LDL, which has the ability to enhance 
monocyte chemotaxis and adhesion.  
 
The main challenge after these results is to discover which are the underlying mechanisms 
implicated in oleic acid beneficial effects. Initially, Tsimikas et al. [148] explained the 
mechanism by which oleic-acid enriched diets decreased lipoprotein susceptibility to 
oxidation, presumably, as a result of the decreased linoleic acid content within lipoprotein. 
However, previous experiments with liposomes progressively enriched in oleic acid but with 
constant amounts of linoleic acid, showed that particles with higher oleic acid concentration 
were less susceptible to oxidation, and monocyte chemotaxis and adhesion were nearly 
completed inhibited when exposed to mild oxidative stress, suggesting that oleic acid may 
have an additional independent mechanism of action [149]. 
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Studies on endothelial cells in vitro have shown that the main dietary PUFA and oleic acid 
may prevent endothelium activation either by inhibiting the expression of adhesion molecules 
or by improving the NO production [150]. Supplementation of endothelial cells with oleic 
acid in vitro reduces endothelial cell sensitivity to oxidants, creating a reduced prooxidant 
environment as a consequence of reduced intracellular ROS [151,152]. In this environment, 
oleate reduces the activation and mRNA expression of NF-κB and AP-1, thereby interfering 
with the endothelial expression of adhesion molecules for circulating monocytes and 
contributing to a direct vascular atheroprotective effect [153-156]. Additionally, cellular 
treatment with this fatty acid protects endothelial cells against cytokine-induced VCAM-1, 
ICAM-1, or E-selectin overexpression [147]. 
 
This condition might occur by two mechanisms: reduced enzymatic production of ROS or 
increased scavenging after their production. It has been suggested that the inhibitory potency 
of unsaturated fatty acids is directly proportional to their number of double bonds [153, 156]. 
According to this, DHA, with 6 double bonds would be 6 times more potent than oleic acid. 
However, addition to oleic acid to the culture medium significantly increases the unsaturation 
index [147], probably through selective displacement of SFA, but not PUFA, in cell 
membrane phospholipids, with a consequent modulation of gene expression for molecules 
involved in monocyte recruitment [153]. Actually, the kinetics of VCAM-1 inhibition by oleic 
acid resembles that of DHA. Similarly to what has been previously shown for DHA, the effect 
is totally independent of the stimulus used: cytokines acting on totally different receptors, 
such as IL-1, TNF-α, IL-4, or LPS, and inducing different responses [157].  
 
Oxidation of fatty acids might help scavenging of ROS, thus reducing the formation of 
superoxides that can be dismutated to hydrogen peroxide, which is in turn responsible for NF-
κB activation [158,159]. Therefore, an alteration of hydrogen peroxide metabolism in 
vascular cells may contribute to the ability of fatty acids to modulate cellular oxidant 
susceptibility [160]. 
 
Experiments with porcine artery endothelial cells (PAEC) supplemented with oleic acid and 
exposed to oxidant conditions by means of hydrogen peroxide treatment showed an attenuated 
increase in intracellular hydrogen peroxide [161]. The consequence was an increase in 
resistance to derangements caused by oxidized LDL and a reduction in oxidant mediated 
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dysfunction [160,162].  Massaro et al. [163] showed that incubating of oleate with cytokine-
stimulated endothelial cells, prevents the depletion of glutathione (GSH) and partially 
prevents stimuli-induced increase of intracellular ROS. This occurred without any change in 
the activity of GSH-related antioxidant enzymes, superoxide dismutase and catalase. These 
authors suggested that oleate may exert direct vascular atheroprotective effects by inhibiting 
endothelial activation through quenching of ROS. In contrast, incubation with linoleic and 
stearic acids reduces GHS levels and increases NFκB [146,155]. Additionally, coincubation 
of linoleic acid with TNFα doubled the production of IL-6 compared with TNFα alone. This 
was concomitant to an increment in the content of arachidonic acid in membrane 
phosphatidylethanolamine. 
 
In contrast with these results, other authors have suggested negative effects of circulating non-
esterified fatty acids like oleic acid in diabetic patients. Experiments with cultured rat aortic 
smooth cells maintained in media containing oleic acid concentrations similar to those in 
diabetic patients showed a significant increase in endothelin-1 receptor amount suggesting 
that it may contribute to the acceleration of atherosclerosis in diabetic patients. [164,165]. 
 
5.2 Effects of minor components of olive oil on endothelial function 
 
5.2.1 Effects of olive oil phenolic compounds  
 
The major phenolic compounds in olive oil, oleuropein, hydroxytyrosol and tyrosol; are 
strong antioxidants and radical scavengers [166], which can help to revert the imbalance 
between increased oxidative stress and impaired antioxidant defence that affects endothelial 
function, and therefore contributes to atherosclerotic disease progression.  
 
Associations between oxidative stress and impaired endothelial function have been 
demonstrated in experimental animal models of atherosclerosis, hypertension, 
hypercholesterolemia and diabetes [167-169]. Reduced bioavailability of NO in a setting of 
increased superoxide anion levels seems to be constant biological changes that occur in the 
vessel wall under these conditions [170]. In fact, it has been described that endothelial 
vasomotor dysfunction could be reversed in these kind of patients by the administration of 
agents capable to scavenging ROS [171-174].  
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A number of papers have reported in vitro experiments evaluating and confirming the 
antioxidant activities and the scavenging potencies of olive oil and its isolated constituents 
[175-179].  
 
The low unsaturation of olive oil fatty acids, in addition to water soluble antioxidant 
protection in the form of phenolic compounds favourably influences a reduced susceptibility 
to oxidation of olive oil-derived lipoproteins [180]. Recently, it has been reported that an 
olive oil intake of 25 mL in a single dose does not promote exacerbated hypertriglyceridemia 
or hyperglycemia, which are linked to postprandial oxidative stress. These authors found a 
postprandial increase of both tyrosol and hydroxytyrosol, two phenolic compounds frequently 
used as markers of olive oil intake. The increased concentration of these phenols in plasma 
may be related to the reduced oxidative stress, since their increase was concomitant to a 
postprandial decrease in plasma oxidized LDL.  
 
Oleuropein and hydroxytyrosol are potent scavengers of ROS and superoxide anion in 
neutrophils [177,179]. Saija et al. [175] hypothesized that whereas hydroxytyrosol can serve 
as scavenger of aqueous peroxyl radicals near the membrane surface, oleuropein acts also as 
scavenger of chain-propagating lipid peroxyl radicals within the membranes. Additionally, 
oleuropein has been shown to increase NO production from LPS-stimulated mouse 
macrophages [181] and to possess a tonic effect toward the inducible form of NO synthase 
(iNOS). Tuck et al. [166], reported that these two phenolic compounds, as well as caffeic acid 
but not tyrosol, can scavenge free radical NO (NO) and peroxynitrite in a concentration 
dependant fashion. Altogether, these features of oleuropein and hydroxytyrsol might 
contribute to increase of NO levels and to prevent formation of the powerful oxidant 
peroxinitrite [182].  
 
Besides the antioxidant properties of the phenolic compounds from extra VOO, anti-
inflammatory effects have been demonstrated in several cell types. De la Puerta et al. [183] 
studied a range of VOO phenolics in rat peritoneal leukocytes, finding inhibition of LTB4 
production by oleuropein glycosyde, caffeic acid and tyrosol. This had already been described 
in human platelets and leukocytes [184,185]. Hydroxytyrosol has also demonstrated 
inhibitory effects on LOX [185] in leukocytes, presumably by penetrating in cell membranes 
[186]. The inhibition of LTB4 production from arachidonic acid may lead to reduced platelet 
aggregation [184,187].  
 18 
 
It has been described that some phenolic compounds may inhibit cytokine and eicosanoid 
production by inhibiting the IL-1β mRNA and protein expression, and the activity and 
transcription of COX-2 [183,185,188], which may contribute to the antiatherogenic properties 
ascribed to extra VOO. Miles et al., [188] showed a very strong effect of oleuropein glycoside 
but none of the phenolic compounds from olive oil studied was able to affect the production 
of IL-6 or TNF-α. However, these authors did not use oleuropein aglycone or hydroxytyrosol 
in their experiments.  
 
Monocyte adhesion to endothelial cells can also been modulated by VOO phenolic 
compounds. Carluccio et al. [189] incubated oleuropein, hydroxytyrosol and tyrosol with LPS 
or cytokine-stimulated HUVECs and observed inhibition of the expression of VCAM-1, I-
CAM-1 and E-selectin and the adhesion of monocytes. The oleuropein aglycone and 
hydroxytyrosol were the most potent phenolic compounds, which is consistent with their 
higher antioxidant activity. In contrast, to the study of Miles et al., [188] the oleuropein 
glycoside showed a low activity on adhesion molecule expression, which was attributed to its 
lower lipophilicity, and the consequent lower incorporation into membranes and interaction 
with lipids. mRNA expression for VCAM-1 was also affected, indicating a pretranscriptional 
action of the phenolic compounds. These authors observed a repression of the transcription 
factors NFκB and AP-1, the interaction of which are known to amplify VCAM-1 promoter 
activation [190]. Very recently, Turner et al. [191] also reported increased VCAM-1 and 
ICAM-1 production by VOO phenolics (namely oleuropein, hydroxytyrosol, tyrosol and 
homovanillic alcohol) but no influence on NO production or platelet aggregation. Activation 
of NF- κB involves complex signal transduction pathways that ultimately result in the 
activation of a specific IκB kinase (IKK) and translocation of NF-κB from cytoplasm to the 
nucleus. In an attempt of elucidating the mechanisms by which phenolic compounds inhibit 
NFκB, Ma et al. [192] showed that these compounds do not inhibit activation of IKK activity, 
degradation of IκBα, a component of the cytoplasmic NFκB complex, or translocation of 
activated NFκB to the nucleus, but they block the formation of NF κB/DNA binding 
complexes. These authors suggested that this blockade involves the antioxidant property of 
the phenolic compounds. 
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5.2.2 Effects of the unsaponifiable fraction 
 
The unsaponifiable fraction of VOO is also rich in other minor components with antioxidant 
and anti-inflammatory properties, such as tocopherols, sterols or terpenic compounds [193-
195].  
 
The investigation of the effects of the unsaponifiable fraction of olive oil as a whole is almost 
an unexplored field. Ochoa et al., [196] investigated the influence of VOO and HOSO, with 
different unsaponifiable fractions on the fatty acid composition and lipid peroxidation of LDL 
in rabbits. The main outcome of the study was the lower susceptibility of LDL oxidation and 
higher antioxidant content in LDL of animals fed the diet enriched in VOO, which was 
attributed to the higher phenolic content in this oil. Unfortunately, as stated above, the 
phenolic compounds of olive oil are not included in the unsaponifiable fraction.  
 
We recently incubated endothelial cells with postprandial TRL derived from the intake by 
healthy subjects of meals containing VOO, HOSO and VOO enriched in its unsaponifiable 
fraction (EVO) to a final concentration of 2.4% [124]. The unsaponifiable fraction of VOO 
was richer in squalene, terpenic compounds and waxes (long-chain fatty alcohols), whereas 
HOSO presented a higher concentration in tocopherols. The total concentration in sterols was 
similar between VOO and HOSO but in EVO, was almost double. We found a reduction in 
the production of PGE2 and TXB2 after the incubation with EVO-TRL, compared with VOO 
and HOSO (Figure 2), but no effect on NO production. These results suggest that minor 
components from VOO that are transported postprandially in TRL may have favourable 
effects on endothelial function by improving the balance between vasoprotective and 
prothrombotic factors released by endothelial cells. Despite the beneficial effects attributed to 
phenolic compounds it is very unlikely that they were responsible for the effects observed in 
this study: firstly, because its concentration in VOO and EVO was very similar, secondly, 
because due to their hydrophilic nature they are readily transported into plasma and not to 
TRL and thirdly because they appear not to affect COX activity [183]. Therefore we 
suggested that tocopherols, sterols or terpenoids might be responsible for the effects observed. 
 
Vitamin E, comprising tocopherols, tocotrienols and some of their derivatives, has a 
protective role against the attacks of free radicals, by acting as lipid based radical chain 
breaking molecules [197]. More recently, non-antioxidant functions of vitamin E have been 
 20 
proposed, in particular as gene regulator, which seems to be unrelated to its radical chain 
breaking potential [198].  
 
Apart from protecting LDL from lipid peroxidation [199-202], α-tocopherol has an inhibitory 
effect on LDL- and cytokine-induced production and expression of adhesion molecules [203-
205] and adhesion of monocytes to endothelial cells, probably by inhibition of ICAM-1 
expression [204,206]. In cells stimulated with IL-1-β, α-tocopherol reduces the upregulation 
of ICAM-1, VCAM-1 [207] and E-selectin [206], but more importantly, it can also regulate 
the production of IL-1-β by down-regulating its gene expression [208]. However, the effect 
on adhesion molecules seems not be mediated by NFκB mobilisation [159,206]. 
 
Vitamin E can also modulate eicosanoid metabolism in endothelial cells. Actually, PGI2 
synthesis in impaired in vitamin E-deficient mice [209-210] and it can restore reduced PGI2 
synthesis in endothelial cells [211,212]. In addition, there are data indicating that α-
tocopherol inhibits 5-LOX [213] and COX-2 [214]. In a series of studies carried out by 
Meidani et al. [215-217] these authors demonstrated that α- ocopherol can eliminate the 
increase in PGE2, TXA 2 and TXB 2 by reducing the activity of COX in LPS-stimulated 
macrophages from aged-mice. This effect was found not to be due to regulation of COX 
transcription or translation, but to the effect of α-tocopherol scavenging hydroperoxydes and 
NO , which leads to lower production of peroxynitrites. There is data suggesting that 
peroxinitrites may modulate COX activation via Ca2+-dependent PLA2 activity and AA 
release [218]. 
 
Finally, pretreatment of endothelial cells with vitamin E, prevents alterations in the plasma 
membrane by hydrogen peroxide [219] and decreases oxidized LDL-mediated degradation of 
I-κB and apoptosis [220]. 
 
However not all tocopherols have same effects: α-tocopherol, but not β-tocopherol can 
regulate AP-1 [221] and integrin [222] gene expression. Inhibition of the induction of 
VCAM-1 and E-selectine by IL-1-β was time and dose-dependent for α-tocopheryl succinate, 
but not for IL-1- β [223]. In fact, α-tocopheryl succinate can inhibit cytokine-induced 
mobilisation of NFκB [223], by activating caspase-3 and caspase-6, which cleave the p65 
subunit of the transcription factor [224,225]. According to Christen et al. [226] γ-tocopherol 
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can inhibit peroxynitrite-induced peroxidation more effectively than α-tocopherol. Hence, α-
tocopherol isomers might inhibit COX activity more effectively than α-tocopherol itself 
[214]. Nevertheless, there is controversy regarding the in vivo and long-term effects of 
vitamin E and it is not clear what amounts or combinations may be beneficial in preventing 
chronic diseases [197].   
 
There are studies in humans and animals evidencing that plant sterol supplementation, 
including the most abundant in VOO, β-sitosterol, can cause a decrease in serum cholesterol 
concentration [227, 228]. One of the principal mechanisms by which this effect has been 
explained is through inhibition of the absorption of cholesterol [229]. Despite of this, a recent 
study carried out by Ho et al. [230] suggests that the mechanisms also involve decreased 
production of the apoB-containing lipoproteins from the liver and intestine. However, very 
little is known about their effect on vascular function. De Jongh et al, [231] administrated a 
mixture of phytosterols (β-sitosterol, campesterol, stigmasterol and others) to 41 children with 
familial hypercholesterolemia, finding a reduction in LDL-cholesterol but no effect on 
endothelial dysfunction as measured by FMD. However, de la Puerta et al. [194] had reported 
that β-sitosterol has antiinflamatory effects as it can reduce the auricular edema induced by 
TPA in mice. The effect was as high as that of hydroxytyrosol or oleuropein. Moreno [232] 
incubated phorbol ester (PMA)-stimulated RAW 264.7 macrophages with β-s osterol, which 
was responsible for a reduction in ROS production and arachidonic acid release. ROS 
modulation may regulate the release of arachidonic acid by phospholipase A2, as well as the 
induction of COX-2 through NFκB activation. By this mechanism β-sitosterol might reduce 
PGE2 and LTB 4 production by macrophages, as observed in this study. Subsequently, this 
author reported that β-sitosterol can regulate the GSH redox cycle, enhancing GSH 
peroxidase and superoxide dismutase activities, hence decreasing superoxide anion levels 
although no ROS scavenger activity was found.  
 
The potential therapeutic importance of olive oil triterpenoids, encompassed of acids and 
alcohols, has not been extensively studied. Although their presence in VOO is very low, in 
olive pomace oil is very significant, as it can be as high as 120 mg/kg. For that reason, the 
concentration of triterpenic alcohols is used as a parameter of purity for the presence of 
pomace oil in VOO [233].  
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Oleanolic acid has been identified in multitude of medicinal plants [234] and has been 
reported to possess a number of biological pharmacological activities, including some 
affecting inflammation [235]. Oleanolic acid inhibits LOX and COX-2 activities [236,237], 
therefore reducing the production of PGE2 and LTB 4. Additionally, it has been shown that 
oleanolic acid can inhibit the generation of the superoxide anion by human neutrophils, which 
might occur through the protein-kinase independent pathway [238]. Although it has been 
attributed anti-inflammatory activities to the triterpenic alcohol erythrodiol, its mechanism of 
action is still unknown. Erythrodiol is able to reduce the edema caused by TPA, with a 
possible action on PLA2 [194]. 
 
We recently developed a study to evaluate the properties as vasodilator agents of oleanolic 
acid and erythrodiol and to determine their mechanism of action [195]. The vasorelaxant 
effect induced by these triterpenoids was studied in isolated thoracic rat aorta. Results from 
this work introduced the first in vitro evidence that oleanolic acid and erythrodiol evoke an 
endothelium-dependent vasorelaxation in rat aorta, and suggested that the mechanism of 
relaxation is mainly mediated by the endothelial production of NO (Figure 3). According with 
the pharmacological effects obtained, it was concluded that oleanolic acid and erythrodiol 
may have interesting therapeutic potential as new vasodilator drugs, being able to protect the 
cardiovascular system. 
 
6. Conclusion 
 
It is becoming clear that the content of oleic acid alone can not fully explain the impact on 
health of olive oil and that being VOO an unique fruit-derived oil it is rich in a number of 
minor compounds with relevant physiological and pharmacological functions. Among these 
compounds, tocopherols and phenolic compounds have demonstrated antioxidant properties, 
which may improve the endothelial function by reducing levels of ROS in the endothelium 
and, consequently, the production of eicosanoids and adhesion molecules. However, there are 
other less studied compounds that have been proved to exert important effects on the 
endothelial function. Phytosterols and triterpenoids have anti-inflammatory and vasorelaxant 
effects, respectively but their roles in the endothelium need to be further studied. The 
increasing investigations on the properties of these minor compounds are not only helping to 
explain some of the classical beneficial effects of the Mediterranean diet and VOO itself but 
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also to the emergence of other olive-derived oils, such as pomace olive oil, which being more 
enriched in these minor components, might be helpful for the prevention of CVD. 
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Table 1. Minor Component Composition of Virgin Olive Oil. 
 
 
Sub-fraction Component Concentration (mg/kg) 
UNSAPONIFIABLE   
 
Squalene 
 
200-7500 
β-Carotene 0.3-0.7 
    
    Hydrocarbons 
Polycyclic aromatic hydrocarbons 
 
Traces 
β-Sytosterol 1800-2600 
Campesterol <4.0% of total sterols 
∆7-Stigmasterol <0.5% of total sterols 
    Sterols 
Brassicasterol 
 
<0.1% of total sterols 
    Terpenic Dialcohols Erythrodyol + Uvaol 
 
6-10 + 18 
α-Tocopherol 60-200 
β+γ-Tocopherol 3% of total tocopherols 
    Tocopherols 
∆-Tocopherol 
 
<2% of total tocopherols 
Tyrosol  
Hydroxytyrosol  
Caffeic acid 50-800 (total phenols) 
PHENOLIC   
COMPOUNDS 
Oleuropein 
 
 
Flavour components Traces OTHERS 
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Figure 1. Proposed model for the action mechanisms of the oleic acid and minor compounds 
from olive oil based on the literature gathered for the present review. Despite the number of 
studies contributing to this model several gaps are still present, which should be filled with 
further investigations. The main mechanism by which the components of olive oil influence 
endothelial activation involves inhibition and/or scavenging of reactive oxygen species (ROS). 
Oleic acid and β-sitosterol may reduce intracellular ROS by creating a less oxidant 
environment through inhibition of intracellular ROS production. β-sitosterol may also 
enhance superoxide dismutase (SOD) activity, hence decreasing superoxide anion (O2-) levels. 
This reduction has also been observed for the terpenoid oleanolic acid, although the 
mechanism is not presently known. Tocopherols and phenolic compounds are potent 
antioxidants that may help to reduce lipid peroxidation and to scavenge intracellular ROS and 
free radical nitric oxide (NO), reducing the formation of peroxynitrite (OONO-). ROS can 
activate the nuclear factor κB (NFκB), which is then translocated into the nucleus, where it 
binds to recognition sequences in DNA in order to induce gene expression. This mobilisation 
of NFκB is blocked by α-tocopheryl succinate but not by α-tocopherol. In contrast, phenolic 
compounds have been proposed to act blocking the formation of NFκB/DNA binding 
complexes. NFκB modulates the expression of cytokines, 5-lipooxygenase (LOX) and 
cyclooxygenase (COX), thereby affecting the levels of adhesion molecules and eicosanoids. 
However, some of the minor compounds of olive oil may act directly on these enzymes and 
cytokines. LOX and COX activities are inhibited at different points by phenolics and 
triterpenoids and IL-1β expression by phenolics and tocopherols, contributing to protect the 
endothelium against vasoconstriction, platelet aggregation and monocyte adhesion. 
Vasodilation is also suggested to be enhanced by oleuropein and oleanolic acid through 
increase of the production of nitric oxide (NO). 
 
Figure 2. Effect of the unsaponifiable fraction of olive oil in TRLs on eicosanoid production. 
HUVEC were incubated for (24 h) with TRL obtained 2 h after the ingestion of high-oleic 
sunflower (HOSO), virgin olive (VOO) or enriched-virgin olive (EVO) oils. Eicosanoid 
released to the medium were determined by EIAs. Results corresponding to PGE2, TXB 2 and 
6-keto-PGF1α are shown in panels A, B and C respectively. a: p<0.05, vs. Control; b: p<0.05, 
vs. HOSO; c: p<0.05, vs. VOO. 
 
Figure 3. Relaxant effect of oleanolic acid (A) and erythrodiol (B) in phenylephrine (10-6M) 
precontracted rat aortic rings. Addition of the NO-synthase inhibitor L-NAME (3x10-4M) 
produced a significant reduction of the endothelium-dependent relaxation to both triterpenic 
compounds (circles) compared to control (squares). ***: p<0.001, vs. Control. 
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